Segmental bone defects
More than one million of the 5.6 million fractures occurring annually in the United States (US) are associated with healing difficulties in which repair processes stop before the break is completely repaired. Problems can occur due to ineffective immobilisation of the broken bone, disruption to the blood supply or infection.

Up to 10 per cent of fractures that heal poorly require bone grafting using either the patient's own bone tissue or that from a donor.

Bone grafting is not a straightforward process. It is greatly limited by a lack of blood supply to the new bone and by the limited number of regenerating bone cells in the grafted tissue.

Other disadvantages of bone grafting are the chronic pain at the donor site where the patient's own bone is used, and the problem of immune rejection where bone is obtained from a donor.

Mesoblast's MPC technology can generate both new bone and new blood vessels, enabling greater bone regeneration. There will be no immune reaction and no donor site, so no chronic pain. Implantation of MPC at the site of poorly-healing fractures is likely to be more effective in less time, while eliminating other complications of bone grafting.

The Technology

 

Last Share Price

August 26 2010- Preliminary 2010 Annual Report

August 26 2010 - Mesoblast Financial Year End Results; Strong Clinical Progress, Major Regulatory Milestone and Enhanced Corporate Strategy

23 August 2010 - EGM documents - Letter from the Chairman, Notice of Meeting, Independent Expert Report.

16 August - Mesoblast on track for phase 3 bone marrow transplant trial following positive meeting with FDA

21 July - Mesoblast receives TGA regulatory approval to commercially manufacture adult stem cell products

12 July - Phase 3 meeting scheduled with FDA following positive results of bone marrow regeneration trial

28 May - Mesoblast featured at ASX Singapore conference highlighting emerging market leaders

19 May - United States FDA Clears Phase 2 Trial for Cervical Spinal Fusion

16 August 2010 - Southern Cross Equities research - Phase III getting ready for takeoff

23 July 2010 - Southern Cross Equities Research – Big Pharma will be watching

21 July 2010 - Southern Cross Equities Research – The clinical endgame nears

17 May 2010 - Southern Cross Equities Research – Capitalising the Stem Cell Opportunity

14 May 2010 - Bioshares

26 February - RBS Equities Research - Mesoblast (Buy) 1H10 - Master Blasters

July 2009 - Chairman’s Letter

May 2009 - Chairman’s Letter

May 2008 - Issue Nine